Article ; Online: Disseminated Mycobacterium avium on HIV/AIDS: Historical and Current Literature Review.
2020 Volume 22, Issue 1, Page(s) 9–15
Abstract: Combination antiretroviral therapy (cART) has changed Mycobacterium avium epidemiology. A significant decrease in the incidence of disseminated M. avium complex: (DMAC) infection was observed between pre-cART and post-cART periods. In contrast, diagnoses ...
| Abstract | Combination antiretroviral therapy (cART) has changed Mycobacterium avium epidemiology. A significant decrease in the incidence of disseminated M. avium complex: (DMAC) infection was observed between pre-cART and post-cART periods. In contrast, diagnoses of DMAC more than doubled from 1990 to 1996. During this time, DMAC prevalence in people living with AIDS (PLHA) in developed countries reached 20-23% overall and >40% in groups with CD4 cell counts <10 cells/mm3. At present, DMAC in PLHA has an incidence of two events per 1000 patient years. Recently, the centers for disease control changed the criteria for MAC primary prophylaxis, where only patients without immediate cART and CD4 cell counts <50 cells/mm3 are prescribed 1200 mg of azithromycin weekly. Treatment is discontinued when patients initiate effective cART. Diagnosing a disseminated M. avium infection is difficult due to the low accuracy of fluid cultures and a lack of diagnostic processes. However, the usefulness of newer molecular techniques such as whole-genome sequencing has not been evaluated for DMAC and HIV/AIDS. As DMAC has a high mortality rate if not properly diagnosed and treated, we performed a literature review of HIV/AIDS and DMAC epidemiology, risk factors, prophylaxis, clinical manifestation, diagnosis, prognosis, and treatment. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Anti-HIV Agents/therapeutic use ; Antitubercular Agents/therapeutic use ; HIV Infections/complications ; HIV-1 ; Humans ; Incidence ; Mycobacterium avium ; Prevalence ; Prognosis ; Risk Factors ; Tuberculosis/complications ; Tuberculosis/drug therapy ; Tuberculosis/epidemiology ; Tuberculosis/microbiology | |||||
| Chemical Substances | Anti-HIV Agents ; Antitubercular Agents | |||||
| Language | English | |||||
| Publishing date | 2020-03-13 | |||||
| Publishing country | Spain | |||||
| Document type | Journal Article ; Review | |||||
| ZDB-ID | 2086783-9 | |||||
| ISSN | 1698-6997 ; 1139-6121 | |||||
| ISSN (online) | 1698-6997 | |||||
| ISSN | 1139-6121 | |||||
| DOI | 10.24875/AIDSRev.20000104 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5711: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.